1
|
Langella J, Finkelman MD, Alon E, Fida Z, Martin A, Amato R. Incidental Findings in Small Field of View Cone-beam Computed Tomography Scans, Part 2: Interpretation with Aid of a Checklist. J Endod 2023; 49:390-394. [PMID: 36702346 DOI: 10.1016/j.joen.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 01/18/2023] [Accepted: 01/18/2023] [Indexed: 01/25/2023]
Abstract
INTRODUCTION Cone-beam computed tomography (CBCT) scans are routinely used by endodontic residents and faculty at Tufts University School of Dental Medicine for diagnostic purposes but are not routinely read for pathologic findings by a radiologist. In a 2017 study by Oser et al (part 1), endodontic residents and a radiologist interpreted CBCT scans taken for endodontic diagnostic purposes, and their findings were compared. The results demonstrated that a radiologist is significantly more likely to report incidental findings in small field of view (FOV) scans. A limitation of this study was that the radiologist used a checklist of common findings to review the scans. The purpose of this study was to examine whether the use of a checklist would improve the sensitivity of the endodontic residents' reporting of incidental findings in small FOV CBCT scans. METHODS The 203 small FOV CBCT scans used in part 1 were obtained and reviewed by endodontic residents in a systematic fashion. Radiographic findings were reported using a blank checklist. The results were compared with those previously reported. RESULTS The radiologist reported abnormalities in 176 of the 203 subjects (87%), and the residents reported abnormalities in 184 of the 203 subjects (91%). There was an increase in false positive findings when the residents were using a checklist. CONCLUSIONS The use of a checklist improved the sensitivity but decreased the specificity of the reporting of incidental findings in small FOV CBCT scans by endodontic residents.
Collapse
Affiliation(s)
- Jessica Langella
- Department of Endodontics, 11th floor, Tufts University School of Dental Medicine, Boston, Massachusetts.
| | - Matthew D Finkelman
- Department of Public Health and Community Service and Director of Biostatistics and Experimental Design, Boston, Massachusetts
| | - Elinor Alon
- Department of Endodontics, 11th floor, Tufts University School of Dental Medicine, Boston, Massachusetts
| | - Zameera Fida
- Boston Children's Hospital/Harvard School of Dental Medicine, Boston, Massachusetts
| | | | - Robert Amato
- Department of Endodontics, 11th floor, Tufts University School of Dental Medicine, Boston, Massachusetts
| |
Collapse
|
2
|
Langella J, Magnuson B, Finkelman MD, Amato R. Clinical Response to COVID-19 and Utilization of an Emergency Dental Clinic in an Academic Institution. J Endod 2020; 47:566-571. [PMID: 33387553 PMCID: PMC7772583 DOI: 10.1016/j.joen.2020.11.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 11/18/2020] [Accepted: 11/24/2020] [Indexed: 12/21/2022]
Abstract
Introduction The spread of coronavirus disease 2019 (COVID-19) in the spring of 2020 resulted in the temporary suspension of elective dental procedures and clinical dental education in academic institutions. This study describes the use of the Tufts University School of Dental Medicine emergency dental clinic during the peak surge in COVID-19 cases in Massachusetts, highlighting the number of endodontic emergencies. Methods Aggregate data from clinical encounters and call records to an emergency triage phone line from March 30 through May 8, 2020, were used to describe the characteristics of dental emergencies, clinical encounters, and procedures performed. Results A total of 466 patient interactions occurred during this period, resulting in 199 patients advised by phone and 267 clinical encounters. The most common dental emergencies were severe dental pain from pulpal inflammation (27.7% of clinical encounters) followed by a surgical postoperative visit (13.1%). The most frequent procedures were extractions (13.9% of clinical encounters) and surgical follow-up (13.5%); 50.2% of the clinical encounters were categorized as aerosol generating, and 86.1% of encounters would have required treatment in a hospital emergency department if dental care was not available. There were no known transmissions of severe acute respiratory syndrome coronavirus-2 among clinic providers, patients, or staff during this period. Conclusions These results highlight the importance of endodontic diagnosis and treatment in the provision of emergency dental care during a pandemic and demonstrate that dental treatment can be provided in a manner that minimizes the risk of viral transmission, maintaining continuity of care for a large patient population.
Collapse
Affiliation(s)
- Jessica Langella
- Department of Endodontics, Tufts University School of Dental Medicine, Boston, Massachusetts.
| | - Britta Magnuson
- Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, Massachusetts; Division of Biostatistics and Experimental Design, Tufts University School of Dental Medicine, Boston, Massachusetts
| | - Matthew D Finkelman
- Division of Biostatistics and Experimental Design, Tufts University School of Dental Medicine, Boston, Massachusetts; Department of Public Health and Community Service, Tufts University School of Dental Medicine, Boston, Massachusetts
| | - Robert Amato
- Department of Endodontics, Tufts University School of Dental Medicine, Boston, Massachusetts
| |
Collapse
|
3
|
Alon E, Amato R. Evaluation of endodontic competency in the COVID-19 era: Problem, solution and results. J Dent Educ 2020; 85:1000-1003. [PMID: 32462660 PMCID: PMC7283880 DOI: 10.1002/jdd.12237] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 05/19/2020] [Accepted: 05/22/2020] [Indexed: 11/11/2022]
Affiliation(s)
- Elinor Alon
- Department of EndodonticsTufts University School of Dental MedicineBostonMassachusettsUSA
| | - Robert Amato
- Department of EndodonticsTufts University School of Dental MedicineBostonMassachusettsUSA
| |
Collapse
|
4
|
Nguyen QBD, Amato R, Riascos R, Ballester L, Tandon N, Blanco A, Esquenazi Y. Fluciclovine, Anti-1-Amino-3-[18F]-Fluorocyclobutane-1-Carboxylic Acid: A Novel Radiotracer for Meningioma. World Neurosurg 2018; 119:132-136. [DOI: 10.1016/j.wneu.2018.07.231] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 07/24/2018] [Accepted: 07/25/2018] [Indexed: 10/28/2022]
|
5
|
Gayed I, Salama V, Dawood L, Canfield S, Wan D, Cai C, Joseph U, Amato R. Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases? Cancer Manag Res 2018; 10:3317-3324. [PMID: 30233247 PMCID: PMC6135075 DOI: 10.2147/cmar.s166218] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients treated with Ra-223 dichloride. It attempts to optimize patients' selection for the best outcome from Ra-223 dichloride therapy. METHODS Consecutive patients who were referred for treatment with Ra-223 dichloride were prospectively followed. Patients' demographics, functional status per the Eastern Cooperative Oncology Group (ECOG) performance score, pain level per the numeric rating score (NRS), prostate-specific antigen (PSA), creatinine, and hematological values were compared at baseline and at the end of therapy. Patients also had a bone scan before starting therapy and at the end of therapy. Patients were divided into the favorable response (FR) group if their pain and/or functional status improved and the unfavorable response (UR) group if they did not improve, deteriorated, or deceased. Bone scan findings before and after Ra-223 dichloride therapy were compared in both the FR and UR groups. RESULTS Twenty patients were treated with Ra-223 dichloride. Twelve patients had innumerable bone metastases, three patients had super scans, and three patients had two to seven bone lesions. Two patients were lost to follow-up after the first injection. There were eight patients in the FR group and 10 patients in the UR group. Patients with UR had mean ECOG and NRS pain scores of 1.3 and 5.0 versus 0.8 and 4.4 in the FR group. The mean PSA and creatinine levels in the UR group were 445.2 ng/mL and 1.2 mg/dL versus 22.7 ng/mL and 1.1 mg/dL in the FR group. The mean hemoglobin, platelets, and absolute neutrophil values were 11.2 g/dL, 314.9 K/cmm, and 7.3 K/cmm in the UR group versus 11.6 g/dL, 207.0 K/cmm, and 6.2 K/cmm in the FR group. Seven of the eight patients with FR had a bone scan at the end of therapy showing improvement in five patients, a mixed response in one patient, and progression in another patient. Five patients in the UR group completed five or six injections and had bone scans showing flare of bone metastases in three patients, progression in one patient, and improvement in the fifth patient. Three patients in the UR group died after the first or second injections. Two of these patients had baseline super scans and the third one had widespread bone metastases. CONCLUSION mCRPC patients with lower PSA levels at baseline and fewer bone lesions are more likely to respond favorably to Ra-223 dichloride therapy.
Collapse
Affiliation(s)
- Isis Gayed
- Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston,
| | - Vivian Salama
- Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center
| | - Lydia Dawood
- Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston,
| | | | - David Wan
- Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston,
| | - Chunyan Cai
- Division of Clinical and Translational Science, Department of Internal Medicine
| | - Usha Joseph
- Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston,
| | - Robert Amato
- Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA
| |
Collapse
|
6
|
Amato R, Dal Monte M, Cervia D, Catalani E, Cammalleri M, Casini G. Neural degeneration mechanisms in diabetic retinopathy: The role of apoptosis and autophagy. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.0f064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- R. Amato
- Department of Biology; University of Pisa; Viterbo Italy
| | - M. Dal Monte
- Department of Biology; University of Pisa; Viterbo Italy
| | - D. Cervia
- Department for Innovation in Biological-Agro-Food and Forest Systems; Università degli Studi della Tuscia; Viterbo Italy
| | - E. Catalani
- Department for Innovation in Biological-Agro-Food and Forest Systems; Università degli Studi della Tuscia; Viterbo Italy
| | - M. Cammalleri
- Department of Biology; University of Pisa; Viterbo Italy
| | - G. Casini
- Department of Biology; University of Pisa; Viterbo Italy
| |
Collapse
|
7
|
Dal Monte M, Amato R, Locri F, Cammalleri M. Nebivolol acts as a beta3-adrenergic receptor agonist in a mouse model of oxygen-induced retinopathy. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.0f084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M. Dal Monte
- Department of Biology; University of Pisa; Pisa Italy
| | - R. Amato
- Department of Biology; University of Pisa; Pisa Italy
| | - F. Locri
- Department of Biology; University of Pisa; Pisa Italy
| | - M. Cammalleri
- Department of Biology; University of Pisa; Pisa Italy
| |
Collapse
|
8
|
Amato R, Dal Monte M, Lulli M, Cammalleri M, Raffa V, Casini G. Functionalized magnetic nanoparticles as a novel strategy for the treatment of diabetic retinopathy. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.0f065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- R. Amato
- Department of Biology; University of Pisa; Pisa Italy
| | - M. Dal Monte
- Department of Biology; University of Pisa; Pisa Italy
| | - M. Lulli
- Department of Experimental and Clinical Biomedical Sciences- General Pathology Unit; University of Florence; Florence Italy
| | - M. Cammalleri
- Department of Biology; University of Pisa; Pisa Italy
| | - V. Raffa
- Department of Biology; University of Pisa; Pisa Italy
| | - G. Casini
- Department of Biology; University of Pisa; Pisa Italy
| |
Collapse
|
9
|
Teh BS, Paulino AC, Lu HH, Chiu JK, Richardson S, Chiang S, Amato R, Butler EB, Bloch C. Versatility of the Novalis System to Deliver Image-Guided Stereotactic Body Radiation Therapy (SBRT) for Various Anatomical Sites. Technol Cancer Res Treat 2016; 6:347-54. [PMID: 17668943 DOI: 10.1177/153303460700600412] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) programs to treat brain tumors were implemented when we first acquired the Brainlab Novalis system in 2003. Two years later, we started an extra-cranial stereotactic radio-ablation or more appropriately a stereotactic body radiation therapy (SBRT) program using the Brainlab Novalis image-guided system at The Methodist Hospital in Houston, Texas. We hereby summarize our initial experience with this system in delivering image-guided SBRT to a total of 80 patients during our first year of clinical implementation, from February 2005 to January 2006. Over 100 lesions in more than 20 distinct anatomical sites were treated. These include all levels of spine from cervical, thoracic, lumbar, and sacral lesions. Spinal lesions encompass intramedullary, intradural, extradural, or osseous compartments. Also treated were lesions in other bony sites including orbit, clavicle, scapula, humerus, sternum, rib, femur, and pelvis (ilium, ischium, and pubis). Primary or metastatic lesions located in the head and neck, supraclavicular region, axilla, mediastinum, lung (both central and peripheral), abdominal wall, liver, kidney, para-aortic lymph nodes, prostate, and pelvis were also treated. In addition to primary radiotherapy, SBRT program using the Brainlab Novalis system allows re-irradiation for recurrence and “boost” after conventional treatment to various anatomical sites. Treating these sites safely and efficaciously requires knowledge in radiation tolerance, fraction size, total dose, biologically equivalent dose (BED), prior radiotherapy, detailed dose volume histograms (DVH) of normal tissues, and the radiosensitive/radioresistant nature of the tumor. Placement of radio-opaque markers (Visicoil, Radiomed) in anatomical sites not in close proximity to bony landmarks (e.g., kidney and liver) helps in measuring motion and providing image guidance during each treatment fraction. Tumor/organ motion data obtained using 4D-CT while the patient is immobilized in the body cast aids in planning treatment margin and determining the need for respiratory motion control, e.g., abdominal compressor, gating, or active breathing control. The inclusion of PET/CT to the Brainlab treatment planning system further refines the target delineation and possibly guides differential fraction size prescription and delivery. The majority of the patients tolerated the SBRT treatment well despite the longer daily treatment time when compared to that of conventional treatment. All patients achieved good pain relief after SBRT. Compared to conventional standard radiotherapy of lower daily fraction size, we observed that the patients achieved faster pain relief and possibly more durable symptom control. Very high local control with stable disease on imaging was observed post SBRT. Our initial experience shows that the Brainlab Novalis system is very versatile in delivering image-guided SBRT to various anatomical sites. This SBRT approach can be applied to either primary or metastatic lesions in the primary, “boost,” or re-irradiation settings. The understanding of fraction size, total dose, BED, and DVH of normal tissues is very important in the treatment planning. Appropriate use of immobilization devices, radio-opaque markers for image-guidance, 4D-CT for tumor/organ motion estimates, and fusion of planning CT scans with biological/functional imaging will further improve the planning and delivery of SBRT, hopefully leading to better treatment outcome.
Collapse
Affiliation(s)
- Bin S Teh
- Department of Radiation Oncology, Radiology, and Genito-urinary Oncology, The Methodist Hospital, The Methodist Hospital Research Institute and Baylor College of Medicine, 6565 Fannin St. MS 121-B, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Li L, Hulsurkar M, Amato R, Chang J, Du G, Li W. Abstract B34: CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Cancer Res 2016. [DOI: 10.1158/1538-7445.tummet15-b34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The epithelial-mesenchymal transition (EMT) confers mesenchymal properties on epithelial cells and has been closely associated with the acquisition of aggressive traits by epithelial cancer cells. To identify novel regulators of EMT, we carried out cDNA screens that covered 500 human kinases. Subsequent characterization of candidate kinases led us to uncover cyclin-dependent kinase-like 2 (CDKL2) as a novel potent promoter for EMT and breast cancer progression. CDKL2-expressing human mammary gland epithelial cells displayed enhanced mesenchymal traits and stem cell-like phenotypes, which was acquired through activating a ZEB1/E-cadherin/beta-catenin positive feedback loop and regulating CD44 mRNA alternative splicing to promote conversion of CD24-high cells to CD44-high cells. Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model. Notably, CDKL2 is expressed significantly higher in mesenchymal human breast cancer cell lines than in epithelial lines, and its over-expression/amplification in human breast cancers is associated with shorter disease-free survival. Taken together, our study uncovered a major role for CDKL2 in promoting EMT and breast cancer progression.
Citation Format: Linna Li, Mohit Hulsurkar, Robert Amato, Jeffrey Chang, Guangwei Du, Wenliang Li. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B34.
Collapse
Affiliation(s)
- Linna Li
- University of Texas Health Science Center at Houston, Houston, TX
| | - Mohit Hulsurkar
- University of Texas Health Science Center at Houston, Houston, TX
| | - Robert Amato
- University of Texas Health Science Center at Houston, Houston, TX
| | - Jeffrey Chang
- University of Texas Health Science Center at Houston, Houston, TX
| | - Guangwei Du
- University of Texas Health Science Center at Houston, Houston, TX
| | - Wenliang Li
- University of Texas Health Science Center at Houston, Houston, TX
| |
Collapse
|
11
|
Morleo M, Amato R, Giaquinto L, Bernardo DD, Franco B. A network-based approach to dissect the cilia/centrosome complex interactome. Cilia 2015. [PMCID: PMC4519165 DOI: 10.1186/2046-2530-4-s1-p87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Affiliation(s)
- M. Dal Monte
- Department of Biology; University of Pisa; Pisa Italy
| | - R. Amato
- Department of Biology; University of Pisa; Pisa Italy
| | - M. Biagioni
- Department of Biology; University of Pisa; Pisa Italy
| | - M. Cammalleri
- Department of Biology; University of Pisa; Pisa Italy
| | - G. Casini
- Department of Biology; University of Pisa; Pisa Italy
| |
Collapse
|
13
|
Li L, Chang J, Du G, Amato R, Li W. Abstract 1433: CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The epithelial-mesenchymal transition (EMT) confers mesenchymal properties on epithelial cells and has been closely associated with the acquisition of aggressive traits by epithelial cancer cells. To identify novel regulators of EMT, we carried out cDNA screens that covered 500 human kinases. Subsequent characterization of candidate kinases led us to uncover cyclin-dependent kinase-like 2 (CDKL2) as a novel potent promoter for EMT and breast cancer progression. CDKL2-expressing human mammary gland epithelial cells displayed enhanced mesenchymal traits and stem cell-like phenotypes, which was acquired through activating a ZEB1/E-cadherin/beta-catenin positive feedback loop and regulating CD44 mRNA alternative splicing to promote conversion of CD24-high cells to CD44-high cells. Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model. Notably, CDKL2 is expressed significantly higher in mesenchymal human breast cancer cell lines than in epithelial lines, and its over-expression/amplification in human breast cancers is associated with shorter disease-free survival. Taken together, our study uncovered a major role for CDKL2 in promoting EMT and breast cancer progression.
Citation Format: Linna Li, Jeffrey Chang, Guangwei Du, Robert Amato, Wenliang Li. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1433. doi:10.1158/1538-7445.AM2015-1433
Collapse
Affiliation(s)
- Linna Li
- University of Texas Health Science Center at Houston, Houston, TX
| | - Jeffrey Chang
- University of Texas Health Science Center at Houston, Houston, TX
| | - Guangwei Du
- University of Texas Health Science Center at Houston, Houston, TX
| | - Robert Amato
- University of Texas Health Science Center at Houston, Houston, TX
| | - Wenliang Li
- University of Texas Health Science Center at Houston, Houston, TX
| |
Collapse
|
14
|
Stockert B, Amato R, Friedell R, Haun C, Perez R, Whang J. Improving recognition of adverse events in the ICU using targeted de-briefing and high-fidelity simulation. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Affiliation(s)
- R Amato
- Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.
| | - K Pautrat
- Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France
| | - M Pocard
- Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France
| | - P Valleur
- Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France
| |
Collapse
|
16
|
Biagi C, Conti V, Montanaro N, Melis M, Buccellato E, Donati M, Covezzoli A, Amato R, Pazzi L, Venegoni M, Vaccheri A, Motola D. Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. Eur J Clin Pharmacol 2014; 70:1505-12. [PMID: 25234795 DOI: 10.1007/s00228-014-1755-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 09/11/2014] [Indexed: 01/28/2023]
Abstract
PURPOSE The purpose of this study is to conduct a comparative analysis of the suspected adverse drug reactions (ADRs) associated with intravitreal bevacizumab, ranibizumab and pegaptanib in the WHO database in order to have a real-life information on these drugs, which now is only based on data coming from clinical trials. METHODS ADR reports for intravitreal use of bevacizumab, ranibizumab and pegaptanib from January 2002 to December 2012 were selected from the WHO-VigiBase. Reporting odds ratio (ROR) with confidence interval of 95 % and p value was calculated. The analysis was performed for drug-reaction pairs. The Medical Dictionary for Regulatory Activities (MedDRA) terminology for ADRs was used. RESULTS The analysis was performed on 3180 reports corresponding to 7753 drug-reaction pairs. Significant RORs for endophthalmitis and uveitis (1.90, 95 % confidence interval (CI) 1.48-2.43, and 10.62, 6.62-17.05, respectively) were retrieved for bevacizumab, and cerebrovascular accident and myocardial infarction produced significant ROR (1.54, 1.14-2.10 and 1.73, 1.18-2.53, respectively) for ranibizumab. Pegaptanib was significantly associated with visual impairment (1.98, 1.12-3.5, p = 0.02), nausea (3.29, 1.57-6.86, p < 0.001), vomiting (2.91, 1.2-7.07, p = 0.01) and drug hypersensitivity (8.75, 3.1-24.66, p < 0.001). CONCLUSIONS Our data showed an elevated disproportionality for cardiovascular ADRs in patients treated with ranibizumab and for infective ocular reactions in those treated with bevacizumab. No relevant safety issues were identified for pegaptanib. These findings suggest bevacizumab as a suitable choice for AMD therapy due to its effectiveness similar to that of ranibizumab, its favourable safety profile and for its lower cost.
Collapse
Affiliation(s)
- C Biagi
- Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, via Irnerio 48, 40126, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Amato R, Legrand G, Pocard M. Management of testicular torsion. J Visc Surg 2014; 151:307-9. [PMID: 24768469 DOI: 10.1016/j.jviscsurg.2014.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- R Amato
- Hôpital Lariboisière, Service de Chirurgie digestive et cancérologique, 2, rue Ambroise-Paré, 75010 Paris, France.
| | - G Legrand
- Hôpital Saint-Louis, Service d'Urologie, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - M Pocard
- Hôpital Lariboisière, Service de Chirurgie digestive et cancérologique, 2, rue Ambroise-Paré, 75010 Paris, France
| |
Collapse
|
18
|
Mehrkhodavandi N, Green D, Amato R. Toothache caused by trigeminal neuralgia of vestibular schwannoma: a case report. [Corrected]. J Endod 2014; 40:1691-4. [PMID: 25260746 DOI: 10.1016/j.joen.2014.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Revised: 03/02/2014] [Accepted: 03/04/2014] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Vestibular schwannoma, also called acoustic neuroma, is a tumor composed of Schwann cells that most commonly involves the vestibular division of the 8th cranial nerve. A thorough medical and dental history and properly conducted diagnostic testing and radiographic evaluation are essential in differentiating odontogenic tooth pain from tooth pain of a nonodontogenic origin. METHODS This report discusses a case of acoustic neuroma mimicking odontogenic pain. A 61-year-old man presented with pain in the lower left quadrant. Medical history revealed peripheral neuropathy and prior exposure to Agent Orange. Diagnostic testing on teeth #19, #20, and #21 ruled out an odontogenic cause for the pain. Brushing of a specific region of the face elicited pain that resembled the patient's chief concern. The patient was referred to a craniofacial pain center with the tentative diagnosis of trigeminal neuralgia. Treatment for trigeminal neuralgia was not successful, prompting referral to the neurosurgery department where magnetic resonance imaging was performed. RESULTS Magnetic resonance imaging revealed a moderate-size, lobular, left cerebellopontine angle mass lesion consistent with acoustic neuroma with compression of the left trigeminal nerve secondary to the lesion. CONCLUSIONS Acoustic neuroma can cause tooth pain secondary to compression of the trigeminal nerve.
Collapse
Affiliation(s)
| | - Daniel Green
- Tufts University School of Dental Medicine, Boston, Massachusetts
| | - Robert Amato
- Tufts University School of Dental Medicine, Boston, Massachusetts.
| |
Collapse
|
19
|
Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:595-604. [PMID: 24452395 DOI: 10.1007/s00280-014-2389-9] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 01/13/2014] [Indexed: 11/30/2022]
Abstract
PURPOSE The platelet-derived growth factor receptor (PDGFR) has an important role in tumorigenesis and tumor progression. Olaratumab (IMC-3G3) is a fully human monoclonal antibody that selectively binds human PDGFRα and blocks ligand binding. This phase I study assessed the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), pharmacokinetics, and preliminary antitumor activity of olaratumab in patients with advanced solid tumors. METHODS Patients were enrolled into five dose-escalating cohorts of 3-6 patients each. Olaratumab was administered intravenously weekly at 4, 8, or 16 mg/kg (cohorts 1-3) or once every other week at 15 or 20 mg/kg (cohorts 4-5), with 4 weeks/cycle. RESULTS Nineteen patients were treated in five cohorts. There were no dose-limiting toxicities; the MTD was not identified with the doses studied. The most common olaratumab-related adverse events (AE) were fatigue and infusion reactions (10.5 % each). With the exception of 1 patient (20 mg/kg) experiencing two grade 3 drug-related AEs after the dose-limiting toxicity assessment period, all drug-related AEs were grade 1 or 2. The trough concentrations (C min) for 16 mg/kg weekly and 20 mg/kg biweekly were higher than 155 μg/mL, and the concentration found to be efficacious in preclinical xenograft models. Twelve patients (63.2 %) had a best response of stable disease [median duration of 3.9 months (95 % CI 2.3-8.7)]. CONCLUSIONS Olaratumab was well tolerated and showed preliminary antitumor activity. RP2Ds are 16 mg/kg weekly and 20 mg/kg biweekly. Phase II studies of olaratumab as monotherapy and in combination are ongoing in several tumor types.
Collapse
Affiliation(s)
- E Gabriela Chiorean
- Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Ave East, G4830, Seattle, WA, 98109, USA,
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer Chemother Pharmacol 2013; 71:1629-34. [PMID: 23604530 DOI: 10.1007/s00280-013-2163-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Accepted: 04/08/2013] [Indexed: 12/19/2022]
Abstract
PURPOSE Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation. METHODS Enrolled patients received ADT in the form of leuprolide every 12 weeks for 24 months with bicalutamide initiating after the completion of chemotherapy. Chemotherapy consisted of ketoconazole and doxorubicin for weeks 1, 3, and 5 and estramustine and docetaxel and for weeks 2, 4 and 6. During weeks 7 and 8, no treatment was received. RESULTS Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %). CONCLUSIONS The treatment demonstrated clinical benefit in all patient subsets with minimal reversible treatment-related adverse events. Subgroup analysis suggests that having prior local therapy resulted in greater PFS and OS.
Collapse
Affiliation(s)
- Robert Amato
- Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston (Medical School)/Memorial Hermann Cancer Center, 6410 Fannin St., Suite 830, Houston, TX 77030, USA.
| | | | | |
Collapse
|
21
|
|
22
|
Ansari M, Guo S, Fakhri S, Citardi MJ, Blanco A, Patino M, Buryanek J, Amato R, Karni R, Brown RE. Sinonasal undifferentiated carcinoma (SNUC): morphoproteomic-guided treatment paradigm with clinical efficacy. Ann Clin Lab Sci 2013; 43:45-53. [PMID: 23462605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Sinonasal undifferentiated carcinoma (SNUC) is a rare and highly malignant tumor that occurs in the nasal cavity and/or paranasal sinuses. Prognosis is poor despite multimodality treatment. Currently, there is no optimal standard of treatment, partially due to a lack of research defining the biology of such tumors. This report discusses two SNUC cases where patients received a novel chemotherapeutic approach using cisplatin, etoposide, Adriamycin (doxorubicin), metformin, and adjuvant melatonin therapies based on morphoproteomic-guidance, followed by consolidation with chemoradiation therapy. This resulted in excellent and objective tomographic and magnetic resonance imaging and clinical responses including complete responses in the induction phase utilizing morphoproteomic-guided therapies. Later, endoscopic excision of the tumor bed failed to reveal any residual tumor. Morphoproteomics helped to define the biology of these SNUC tumors and provided targets for the agents employed, creating a new treatment paradigm for such tumors. This treatment regimen poses a new effective regimen to treat SNUC.
Collapse
Affiliation(s)
- Maria Ansari
- Division of Oncology, Department of Internal Medicine, University of Texas Medical School at Houston and Memorial Hermann Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Amato R, Melnikova V, Pace M, Sukumaran S, Garza M, Redden B, Woo J, Anderes K, Davis D. 215 Circulating Tumor Cells as Surrogate Biomarkers of Epithelial Mesenchymal Transition and Metastatic Phenotype in Prostate Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72013-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Amato R, Scumaci D, D'Antona L, Iuliano R, Menniti M, Di Sanzo M, Faniello MC, Colao E, Malatesta P, Zingone A, Agosti V, Costanzo FS, Mileo AM, Paggi MG, Lang F, Cuda G, Lavia P, Perrotti N. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene 2012; 32:4572-8. [PMID: 23108393 DOI: 10.1038/onc.2012.470] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2012] [Revised: 08/01/2012] [Accepted: 08/21/2012] [Indexed: 12/16/2022]
Abstract
The serum- and glucocorticoid-regulated kinase (Sgk1) is essential for hormonal regulation of epithelial sodium channel-mediated sodium transport and is involved in the transduction of growth factor-dependent cell survival and proliferation signals. Growing evidence now points to Sgk1 as a key element in the development and/or progression of human cancer. To gain insight into the mechanisms through which Sgk1 regulates cell proliferation, we adopted a proteomic approach to identify up- or downregulated proteins after Sgk1-specific RNA silencing. Among several proteins, the abundance of which was found to be up- or downregulated upon Sgk1 silencing, we focused our attention of RAN-binding protein 1 (RANBP1), a major effector of the GTPase RAN. We report that Sgk1-dependent regulation of RANBP1 has functional consequences on both mitotic microtubule activity and taxol sensitivity of cancer cells.
Collapse
Affiliation(s)
- R Amato
- Department of Human Health, University Magna Graecia at Catanzaro, Campus S Venuta, Località Germaneto Viale Europa, Catanzaro, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Amato R, Zhai J, Willis J, Saxena S, DeFoe M. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2012; 10:153-8. [PMID: 22551785 DOI: 10.1016/j.clgc.2012.03.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Revised: 02/13/2012] [Accepted: 03/06/2012] [Indexed: 01/16/2023]
Abstract
PURPOSE Sorafenib has been demonstrated as second-line therapy, with limited significant adverse events at a dose of 400 mg twice a day (b.i.d.) in patients with metastatic renal cell carcinoma. This study evaluated the ability of patients to dose-escalate, response rate, progression-free survival (PFS), and overall survival. METHODS The initial dose of sorafenib was 400 mg b.i.d.. Dose escalation of sorafenib to 600 mg b.i.d. occurred from days 29-56 and increased to 800 mg b.i.d. on day 57 and beyond as tolerated. Dose modifications were performed for toxicity per the National Cancer Institute Common Toxicity Criteria version 3.0. The patients were evaluated every 2 cycles (8 weeks) by using Response Evaluation Criteria in Solid Tumors version 1.0. RESULTS Forty-four patients were evaluable for response. Median age was 62.5 years, 39 patients had a Karnofsky Perfomance Status of 100%. Twenty-two patients received no prior therapy. Of the evaluable patients, 42 were dose escalated to 600 mg b.i.d., and 74% (31) of these were further dose escalated to 800 mg b.i.d.. Eight patients had a complete response (CR), 13 patients demonstrated a partial response (PR), and 21 patients had stable disease. Common treatment-related adverse events included hypertension, hand-foot syndrome, skin rash, diarrhea, dry skin, alopecia, and facial redness. DISCUSSION The majority of patients were escalated to 600 mg b.i.d. or 800 mg b.i.d.. Intrapatient dose-escalated sorafenib has promising antitumor activity as demonstrated by a 48% CR-PR rate (21 patients). Antitumor activity is further suggested by a prolonged PFS ≥6 months in 64% (28) of patients. Significant antitumor activity and reversible adverse events has been demonstrated in escalated doses of sorafenib.
Collapse
Affiliation(s)
- Robert Amato
- Division of Oncology, Department of Internal Medicine, University of Texas, Health Science Center at Houston (Medical School)/Memorial Hermann Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | |
Collapse
|
26
|
Affiliation(s)
- R Amato
- American Memorial Hospital, CHU Reims, 47, rue Cognacq-Jay, 51100 Reims, France.
| | | | | |
Collapse
|
27
|
Abstract
INTRODUCTION The efficacy of sequential everolimus (RAD001, Afinitor®), an orally administered inhibitor of mammalian target of rapamycin (mTOR), is one of the therapeutic options in patients with advanced renal cell cancer (RCC). The purpose of this review is to discuss the mTOR pathway and to update current knowledge of the role of everolimus in metastatic RCC. AREAS COVERED The function of mTOR and its inhibition, the early development trials of everolimus, the Phase II trial that lead to the Phase III study and ultimately to FDA approval are all discussed in this review. Literature utilized for this review consists of PUBMED for both description of the mTOR pathway and its role, in addition to publications using everolimus in RCC. EXPERT OPINION Everolimus is currently the only agent with a proven progression-free survival improvement for patients who progressed on a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Future studies may further shed light on the most optimal use of everolimus.
Collapse
Affiliation(s)
- Robert Amato
- UT Medical School at Houston -- Internal Medicine, Division of Oncology, Houston, TX 77030, USA.
| |
Collapse
|
28
|
Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 2010; 69:1286-90. [PMID: 1371235 DOI: 10.1002/cncr.2820690535] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A retrospective review was done on all high volume choriocarcinomas and other germ cell tumors of men with serum beta-human chorionic gonadotropin (beta-HCG) levels greater than 50,000 mIU/ml to determine the incidence and characteristics of hyperthyroidism in this setting. Nineteen patients were identified with high beta-HCG levels, but because 2 did not have thyroid function tests performed, the cases of only 17 patients were evaluable. Of these, 14 (82%) had primary testicular carcinoma and 3 (18%) had extragonadal tumors. Beta-HCG levels on presentation ranged from 80,000 to 3,058,000 mIU/ml, with a median of 243,500 mIU/ml. Seven of the 17 evaluable cases (41%) had T4 serum levels higher than 12 micrograms/dl (normal level 4 to 12 micrograms/dl) with a median value of 15.4 micrograms/dl (range, 12.6 to 33.5 micrograms/dl); serum T4 levels correlated with beta-HCG levels (r = 0.84). All seven patients with elevated T4 levels had beta-HCG values greater than 200,000 mIU/ml, and three of these seven had clinical manifestations that could be attributed to an elevated serum T4; only one patient required specific antithyroid treatment; and after control of primary disease, all other patients had normalization of thyroid function. The most common manifestations of hyperthyroidism in our series were tachycardia, hypertension, and a systolic flow murmur; none of the patients had thyroid gland enlargement. We conclude that subclinical hyperthyroidism is a relatively common phenomenon in germ cell tumors of men with high levels of beta-HCG and that control of the primary disease results in serum T4 level normalization.
Collapse
Affiliation(s)
- S A Giralt
- Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030
| | | | | | | | | |
Collapse
|
29
|
Hawkins R, Harrop R, Naylor S, Easty S, McDonald M, Tomczak C, Szczylik C, Amato R. 17LBA TRIST: A randomised, double blind, placebo controlled phase III study of MVA-5T4 in metastatic renal cancer patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72052-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
30
|
Abstract
e16056 Background: Everolimus, a mTOR inhibitor and Sorafenib, a Raf kinase inhibitor had shown their efficacy in RCC, as single agents. Combining these two active agents could have potential additive or synergistic effects. We conducted a phase I study to evaluate the maximum tolerated dose (MTD) of this combination in patients with progressive mRCC. Methods: Patients predominantly had clear cell RCC, and progressive measurable diseases on prior treatments including immunotherapy, TKI and/or Everolimus. Patients were evaluated weekly for toxicities and every 8 weeks for radiological response, including at least both PET/CT and CT scans at baseline and 1st staging. Patients received daily Everolimus and twice daily sorafenib both orally at escalating dose levels of 2.5mg/400mg (dose level 0), 5mg/400mg (+1), and 10mg/400mg (+2). Results: 18 patients with mRCC were enrolled and 15 patients were evaluable. 6 patients were treated on dose level 0, dose- limited toxicity (DLT) was found in 2/6 patients, one with thrombocytopenia/leukopenia, the other with pneumonitis; 6 patients were treated on dose level +1, DLT of pulmonary embolism was found in 1/6 patient; and 3 patients were treated on dose level +2, without DLT. The most common side effect was grade 1/2 hand-foot syndrome (4/15, 27%). The MTD was dose level +2. Overall response by RECIST was 27% (4/15 patients): pathological complete response (CR) was 6% (1/15); radiographic CR was 6% (1/5); surgical CR after resection was 6% (1/15). 47% (7/15) of the patients had stable disease. Decreased FDG uptake was found in 67% (10/15) of the patients. The median PFS was 5.53 months (range, 1.4–14.7), and OS was 7.9 months (range, 2.3–23). Conclusions: The MTD of combining daily Everolimus 10mg and twice daily sorafenib 400mg are safe and effective for progressive metastatic RCC. The phase II trial is planned to start in early 2009. [Table: see text]
Collapse
Affiliation(s)
- P. Cen
- University of Texas Medical School, Houston, TX
| | - A. Daleiden
- University of Texas Medical School, Houston, TX
| | - G. Doshi
- University of Texas Medical School, Houston, TX
| | - R. Amato
- University of Texas Medical School, Houston, TX
| |
Collapse
|
31
|
Doshi G, Cen P, Ramirez P, Amato R. Granulocyte macrophage: Colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone as second-line therapy in patients (Pts) with progressive hormone refractory prostate cancer (HRPC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16033 Background: A variety of docetaxel regimens have been tested in HRPC pts, yielding response rates between 38% - 69%. Docetaxel therapy has been widely used as first line therapy. Second line therapies, which are non - taxane based with comparable activities do not exist. This trial is built on the significant body of work which has demonstrated anti-tumor activity of GM-CSF, Ketoconazole and Mitoxantrone alone and in combination in pts with HRPC. The trial is designed to assess the combination of all three agents. Methods: No more than two prior chemotherapy regimens (one which contained docetaxel), progressive disease, and adequate marrow / organ function. Treatment consisted of: Ketoconazole daily 400mg po tid, GM-CSF subcutaneous 250mcg / m2 (14 days on/ 7 days off) and Mitoxantrone 12mg / m2 every 3 weeks (maximum cumulative dose of 140mg / m2), until either the completion of Mitoxantrone or maximum anti-tumor benefit. Pts continued Ketoconazole/ GM-CSF until disease progression. PSA was evaluated every 3 weeks and radiographic studies were performed every 9 weeks. Results: 31 pts were enrolled; 4 pts with PSA only, 9 bone only, 5 soft tissue only, and 13 bone and soft tissue. 2 pts withdrew from study due to toxicity. 8 pts had a PSA response of ≥ 50%, 5 pts had a PSA response of ≥ 80%, and 7 pts had a PSA response of ≥ 90%. 9 pts progressed. The majority of pts had stabilization of their bone and soft tissue involvement and 2 pts with nodal involvement demonstrated a radiographic CR. Significant adverse events included grade III/IV neutropenia, thrombocytopenia, and nausea. Median duration of treatment was 6.22 months (range 2 months - 20.5 months). Conclusions: GM-CSF, Ketoconazole and Mitoxantrone in combination demonstrate significant anti-tumor activity and reversible toxicity in pts who have failed prior docetaxel therapy. Information regarding PSA response, radiographic outcome and adverse event data will be presented. This data warrants further investigation such as a randomized phase II study. [Table: see text]
Collapse
Affiliation(s)
- G. Doshi
- University of Texas Medical School, Houston, TX
| | - P. Cen
- University of Texas Medical School, Houston, TX
| | - P. Ramirez
- University of Texas Medical School, Houston, TX
| | - R. Amato
- University of Texas Medical School, Houston, TX
| |
Collapse
|
32
|
Amato R, Hernandez-McClain J, Harrop R, Cen P, Doshi G. Vaccination of renal cell cancer (RCC) patients with modified vaccinia Ankara (MVA) delivering tumor antigen 5T4 administered alone or with interleukin 2 (IL-2) or interferon-alpha (IFN). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3026 Background: The attenuated vaccinia virus (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). More than 90% of RCCs overexpress the 5T4 antigen. A series of clinical trials were conducted to evaluate the effectiveness of MVA 5T4 as a single agent or in combination with either IL-2 or IFN. Methods: Eligibility: Pathologic diagnosis of clear cell or papillary RCC, progressive measurable metastases, any prior therapy, adequate physiological parameters, Karnofsky performance status ≥ 80%, and no active CNS involvement. A regimen of MVA 5T4 alone or in combination with IL-2 or IFN was given. Results: A total of 53 pts received MVA 5T4 alone or in combination with IL-2 or IFN. 13 pts received MVA 5T4 alone, 25 pts received low dose subcutaneous IL-2, and 15 pts received IFN. Clinical responses were assessed by measuring changes in tumor burden via computed tomography or magnetic resonance imaging scan. 5T4-specific cellular and humoral responses were monitored throughout the study. 5T4 was well tolerated with no serious adverse events attributed to vaccination. Of 48 intention-to-treat pts, 43 mounted 5T4-specific antibody responses. 2 pts showed a complete response for > 36 months and 2 other pts had a partial response for > 24 months and 12 months respectively. 20 pts demonstrated disease stabilization for ≥ 3 months. Median progression-free survival and overall survival for all pts was 3.6 months (range 0.8–29.7) and 13.2 months (range 1–38) respectively. A significant relationship was detected between the magnitude of 5T4-specific antibody response and overall survival. Conclusions: 5T4, whether administered alone or in combination, was well tolerated. High frequency of 5T4-specific immune responses and associated enhanced patient survival is encouraging and warrants further investigation. [Table: see text]
Collapse
Affiliation(s)
- R. Amato
- University of Texas Medical School, Houston, TX; Oxford BioMedica, Oxford, United Kingdom
| | - J. Hernandez-McClain
- University of Texas Medical School, Houston, TX; Oxford BioMedica, Oxford, United Kingdom
| | - R. Harrop
- University of Texas Medical School, Houston, TX; Oxford BioMedica, Oxford, United Kingdom
| | - P. Cen
- University of Texas Medical School, Houston, TX; Oxford BioMedica, Oxford, United Kingdom
| | - G. Doshi
- University of Texas Medical School, Houston, TX; Oxford BioMedica, Oxford, United Kingdom
| |
Collapse
|
33
|
Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX, Gao Y, Mai W, Furge K, Qian CN, Amato R, Butler EB, Teh BT, Teh BS. Radiosensitization by Inhibiting STAT1 in Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys 2009; 73:288-95. [DOI: 10.1016/j.ijrobp.2008.08.043] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2007] [Revised: 08/26/2008] [Accepted: 08/28/2008] [Indexed: 12/01/2022]
|
34
|
Hagenkord JM, Parwani AV, Lyons-Weiler MA, Alvarez K, Amato R, Gatalica Z, Gonzalez-Berjon JM, Peterson L, Dhir R, Monzon FA. Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors. Diagn Pathol 2008; 3:44. [PMID: 18990225 PMCID: PMC2588560 DOI: 10.1186/1746-1596-3-44] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2008] [Accepted: 11/06/2008] [Indexed: 12/15/2022] Open
Abstract
Background Renal epithelial tumors are morphologically, biologically, and clinically heterogeneous. Different morphologic subtypes require specific management due to markedly different prognosis and response to therapy. Each common subtype has characteristic chromosomal gains and losses, including some with prognostic value. However, copy number information has not been readily accessible for clinical purposes and thus has not been routinely used in the diagnostic evaluation of these tumors. This information can be useful for classification of tumors with complex or challenging morphology. 'Virtual karyotypes' generated using SNP arrays can readily detect characteristic chromosomal lesions in paraffin embedded renal tumors and can be used to correctly categorize the common subtypes with performance characteristics that are amenable for routine clinical use. Methods To investigate the use of virtual karyotypes for diagnostically challenging renal epithelial tumors, we evaluated 25 archived renal neoplasms where sub-classification could not be definitively rendered based on morphology and other ancillary studies. We generated virtual karyotypes with the Affymetrix 10 K 2.0 mapping array platform and identified the presence of genomic lesions across all 22 autosomes. Results In 91% of challenging cases the virtual karyotype unambiguously detected the presence or absence of chromosomal aberrations characteristic of one of the common subtypes of renal epithelial tumors, while immunohistochemistry and fluorescent in situ hybridization had no or limited utility in the diagnosis of these tumors. Conclusion These results show that virtual karyotypes generated by SNP arrays can be used as a practical ancillary study for the classification of renal epithelial tumors with complex or ambiguous morphology.
Collapse
Affiliation(s)
- Jill M Hagenkord
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Chiorean E, Sweeney C, Youssoufian H, Fox F, Katz T, Rowinsky E, Amato R. 511 POSTER Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72445-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
36
|
Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino AC. Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) 2008; 22:782-797. [PMID: 18619121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
More than 100,000 new cases of bone metastases are diagnosed each year, and they present an important clinical problem. They cause significant morbidity and quality-of-life issues in cancer patients. Conventional external-beam radiotherapy is currently the most common method to treat these metastases, with several randomized controlled trials showing no difference in effectiveness between multiple- and single-dosing treatment regimens. A newer technology to treat bone metastases is stereotactic body radiotherapy (SBRT), a radiation delivery method that allows for a large ablative dose to be accurately given to the target over one to a few fractions. This review details the role of SBRT in painful bone metastases, primarily in the vertebral column, but in other bony sites as well, its unique advantages and disadvantages, and its role in the treatment of tumors traditionally deemed radioresistant. Toxicity to surrounding normal tissues and patterns of local failures are also addressed.
Collapse
Affiliation(s)
- Pavan Jhaveri
- Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
5107 Background: RAD001 is an oral mammalian target of Rapamycin (mTOR) inhibitor. Three mechanisms of anti-tumor activity; shuts down tumor response to nutrients and growth factors; cell cycle arrest at late G1 and anti-angiogenesis via VEGF. Molecular alterations in the mTOR modular pathway increase sensitivity in PTEN deficient tumors such as RCC. Endpoints: time-to-progression (TTP), response rate (RR), overall survival (OS), toxicity, and to assess changes in metabolic imaging utilizing CT-PET. Methods: Eligibility included; predominant clear cell, progressive measurable MRCC, adequate organ/marrow function, zubrod performance status (ZPS) = 2, no more than 1 prior therapy, and no active CNS involvement. RAD001 is given orally at a dose of 10mg daily without an interruption (28-day cycle), with dose modifications for toxicity. Re-evaluation was assessed every 2 cycles (8 weeks). RECIST criteria is utilized. TTP and OS are determined from entry into the study. Results: 41 pts have been enrolled. 37 pts are evaluable for response/toxicity. 2 pts toxicity only. 2 pts screened failures. 31 were male/8 female, median age 60 (38–80) years. 31 pts received prior therapy. 23 pts had a ZPS of 0, 13 /1 and 3/2. Sites of disease included; lung, nodal, liver, bone, adrenal, and kidney. 9 pts had 1 metastatic site, 17 pts/2 and 13 pts/3 or more. 15 pts continue to receive RAD001. 12 pts had partial responses, 19 pts were stable for 3+ months. Median duration of therapy is 8+ (range 01–20+) months. Treatment related adverse events; mucositis, skin rash, pneumonitis, hypophosphatemia, hyperglycemia, hypertriglyceridemia, hypercholesterolemia, thrombocytopenia, anemia and elevated LFTs. PET scans have demonstrated decreased metabolic activity in responding or stable pts. Median overall survival is 11.5+ months (range 01–20+). Conclusion: RAD001 has promising anti-tumor activity in pts with MRCC demonstrated by partial response rate. Anti-tumor activity is further suggested by prolonged TTP =3 months. Anti-tumor activity, toxicity and metabolic imaging correlation will be presented. An additional 40 pts who failed prior sunitinib or sorafenib therapy are being enrolled. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Jac
- The Methodist Hospital Research Institute, Houston, TX
| | - S. Giessinger
- The Methodist Hospital Research Institute, Houston, TX
| | - M. Khan
- The Methodist Hospital Research Institute, Houston, TX
| | - J. Willis
- The Methodist Hospital Research Institute, Houston, TX
| | - S. Chiang
- The Methodist Hospital Research Institute, Houston, TX
| | - R. Amato
- The Methodist Hospital Research Institute, Houston, TX
| |
Collapse
|
38
|
Cao A, Hernandez-McClain J, Willis J, Harrop R, Shingler W, Chikoti P, Drury N, Amato R. Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3069 Background: MVA 5T4 consists of the highly attenuated modified Vaccinia Ankara virus containing the gene encoding the human TAA 5T4. Ninety percent or more of RCCs overexpress the 5T4 antigen. A series of clinical trials were conducted to evaluate the effectiveness of MVA 5T4 as a single agent or in combination with Interleukin-2 or Interferon Alpha 2B. Methods: Eligibility: pathologic diagnosis of clear cell or papillary RCC, progressive measurable metastases, any prior therapy, adequate physiologic parameters, Karnofsky performance status (KPS) = 80%, and no active CNS involvement. A regimen of MVA 5T4 alone or in combination with IFN or IL-2 was given. Results: A total of 41 patients received MVA 5T4 alone or in combination. 33 patients received MVA 5T4 with low dose IL-2 or IFN. 23 pts had clear cell; 12 papillary; 5 mixed clear cell; and 1 mixed papillary. 19 pts continue to receive therapy. 2 pts (both clear cell RCC) developed complete responses, 3 pts/partial responses (2 clear cell, 1 papillary) 8 pts/stable for 3+months and 6 pts are too early to be staged at this time. Median duration of therapy is 3.0+ (1+-13+) months. Conclusion: Although comparable antibody response were observed in papillary and clear cell histotypes, clear cell patients appeared to be more likely to respond in terms of clinical benefit parameters, to be presented. Of note is that preliminary analysis of clear cell patients suggests a relationship between the anti-5T4 immune response and tumor response. With the immunological potency and encouraging clinical activity, the future research will focus on the phase 3 randomized, double-blind, placebo controlled parallel group study to investigate whether MVA 5T4, added to first line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell as well as studies to further optimize MVA 5T4 potency. [Table: see text]
Collapse
Affiliation(s)
- A. Cao
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - J. Hernandez-McClain
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - J. Willis
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - R. Harrop
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - W. Shingler
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - P. Chikoti
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - N. Drury
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| | - R. Amato
- The Methodist Hospital Research Institute, Houston, TX; Oxford Biomedica UK, Ltd., Oxford, United Kingdom
| |
Collapse
|
39
|
Messmann R, Amato R, Hernandez-McClain J, Conley B, Rogers H, Lu J, Low P, Bever S, Morgenstern D. A phase II study of FolateImmune (EC90 with GP1–0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with refractory or metastatic cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.13516] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13516 Background: FolateImmune is a folate-receptor (FR)-targeted immunotherapy that induces an immune response against tumor cells by marking them with a folate-hapten conjugate. The conjugate is specifically designed to target FR, which is over-expressed in a variety of cancers. FolateImmune therapy is comprised of a vaccine fluorescein conjugate (EC90), an adjuvant (GP-0100), and a folate-hapten conjugate (EC17). Patients (pts) receive a series of subcutaneous (SQ) injections of EC90 vaccine to stimulate the production of antibodies to the fluorescein-hapten, followed by SQ injections of EC17, which forms a molecular bridge between the tumor cell and the endogenous circulating anti-fluorescein IgG antibody. This is thought to initiate an Fc-mediated immune response leading to antibody-dependent cellular cytotoxicity and/or phagocytosis. IL-2 and IFN are utilized at low doses (7 MIU and 3 MIU, respectively) to further promote an immune response. The Phase Ib objective is to determine the safety of EC90 vaccine/EC17 folate-targeted therapy in combination with IL-2 and IFN. The previous phase I trial explored the safety of FolateImmune without cytokines. Methods: This phase 1b safety study treated eligible patients with FolateImmune therapy at dose levels of 1.2 mg EC90 and EC17 of 0.3 mg/kg. Results: As of Jan 2, 2007, all patients have tolerated therapy without significant toxicity. Grade 1–2 toxicity included: chills, fever, and nausea. One patient has had a minor response and continues on study. Laboratory studies revealed decline in circulating FR+ cells. Of 6 pts enrolled, 5 had a pathologic classification of renal cell cancer (RCC). Conclusion: Preliminary data suggest that FolateImmune therapy, with the addition of low dose cytokines, may be administered in a safe and well-tolerated manner. Phase II trials are planned for RCC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Messmann
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - R. Amato
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - J. Hernandez-McClain
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - B. Conley
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - H. Rogers
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - J. Lu
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - P. Low
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - S. Bever
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| | - D. Morgenstern
- Endocyte Inc, West Lafayette, IN; The Methodist Hospital Research Institute, Houston, TX; Michigan State University, Lansing, MI
| |
Collapse
|
40
|
Fu X, Nakamori M, Tao L, Amato R, Zhang X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007. [DOI: 10.3892/ijo.30.6.1561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
41
|
Teh BS, Bloch C, Paulino AC, Shen S, Hinckley L, Baskin D, Butler EB, Amato R. Pathologic Complete Response in Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery. Clin Genitourin Cancer 2007; 5:334-7. [PMID: 17645831 DOI: 10.3816/cgc.2007.n.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Renal cell carcinoma (RCC) is often regarded as a radiation-resistant tumor. However, radiation therapy (RT) in the form of stereotactic radiosurgery (SRS) or whole-brain irradiation has been used to treat brain metastases from RCC. To date, there have been no clinical pathologic correlative findings before and after RT. Herein, we present a case of a patient with brain metastases from RCC treated with SRS. The diagnosis of clear-cell RCC was made in 2001 after right radical nephrectomy. He was also found to have lung metastases at diagnosis. He presented with neurologic symptoms in 2004, and magnetic resonance imaging showed 3 brain lesions with a significant amount of edema consistent with brain metastases. The largest lesion caused a midline shift and was surgically resected. Pathology revealed metastatic RCC. The other 2 smaller brain lesions were treated at 20 Gy respectively with shaped-beam SRS using the BrainLab Novalis system. No whole-brain irradiation was delivered. However, the patient had difficulty weaning off his steroids, and a magnetic resonance imaging performed 6 months after SRS was read as "progression of the lesions." He then underwent resection of both the irradiated brain lesions. Pathologic examination revealed necrotic tissues without any viable tumor identified. The patient has since been doing very well, now 18 months after SRS and 5 years from the initial diagnosis. This is the first reported case that demonstrates that precise high-dose radiation in the form of SRS can cause significant tumor cell death (pathologic complete response) in radiation-resistant brain metastases from RCC. This finding also provides a rationale to deliver stereotactic body RT for primary and metastatic RCC extracranially. A prospective clinical trial using stereotactic body RT for primary and metastatic RCC is under way.
Collapse
Affiliation(s)
- Bin S Teh
- Department of Radiology, Section of Radiation Oncology, Baylor College of Medicine, Houston, TX, USA.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Fu X, Nakamori M, Tao L, Amato R, Zhang X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007; 30:1561-7. [PMID: 17487379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
Abstract
Conditionally replicating (oncolytic) herpes simplex viruses (HSVs) have shown clear potential as effective agents for the treatment of solid tumors such as renal cell carcinoma (RCC). To enhance the oncolytic capabilities of first-generation HSVs, we recently developed two new constructs. Synco-2D is derived from HSV-1 and contains two mechanisms to induce cell membrane fusion. FusOn-H2 is derived from HSV-2. It selectively targets the activated Ras signaling pathway in tumor cells and also has the ability to induce cell membrane fusion and apoptosis. We studied the in vitro and in vivo antitumor effects of both Synco-2D and FusOn-H2 against RCC. Both Synco-2D and FusOn-H2 lysed human RCC cells in vitro much more readily than did Baco-1. For in vivo studies, the oncolytic viruses were administered either intratumorally or intravenously to nude mice bearing xenografted human RCC, and the tumor growth rate and animal survival were monitored after treatment. In most instances, the results were compared with those for a first-generation non-fusogenic oncolytic HSV (Baco-1). A single intratumoral injection of either Synco-2D or FusOn-H2 produced a striking effect against xenografted human RCC, in contrast to Baco-1, which produced only moderate antitumor activity. Two intravenous injections of Synco-2D also inhibited the growth of human RCC xenografts, while Baco-1 injections via the same route lacked any measurable antitumor effect. These data demonstrate that the newly constructed oncolytic HSVs have potent activity against established RCC in animal models. Clinical trials to validate these results in cancer patients appear warranted.
Collapse
Affiliation(s)
- Xinping Fu
- Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | |
Collapse
|
43
|
Amato R, Karediy M, Cao A, Khan M, Naylor S, McDonald M, Harrop R, Shingler W, Chikoti P, Drury N. 113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC). EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70119-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
44
|
|
45
|
Abstract
4533 Background: Immunomodulatory drugs are compounds that originated via the deliberate structural modification of thalidomide. Lenalidomide (Revlimid) is a derivative with enhanced immunological and anti-angiogenic properties lacking toxicities associated with thalidomide. Objectives were to determine response rate, time to progression (TTP), one-year survival, and toxicity in patients with progressive MRCC. Methods: Eligibility included: progressive measurable MRCC, adequate organ/marrow function, zubrod performance status (ZPS) ≤ 2, ≤ 1 prior therapy, and no active CNS involvement. Lenalidomide is administered orally at a dose of 25mg daily for 21 days with 7 days rest (28-day cycle), with dose modifications for toxicity. Re-evaluation is done every 3 cycles (12 weeks). RECIST criteria is utilized to determine response rate. TTP is determined from entry into study. Results: 40 pts enrolled. 30 male/10 female, range 38–73 (median 63) years. 38 pts had clear cell carcinoma; 2 pts with papillary. 24 pts received prior immunotherapy and/or chemotherapy. 3 pts met criteria for good prognosis, 33 intermediate and 4 poor. Sites of disease included: lung, nodal, bone, adrenal, kidney, and liver. 17 pts had 1 metastatic site, 13 pts 2 metastatic sites, and 10 pts 3 or more metastatic sites. 36 pts completed at least 12 weeks of therapy. 4 pts had early progressive disease. 1 pt had a CR, 2 pts achieved a PR. 52% of pts had a prolonged TTP ≥ 6 months and 25% ≥ 12 months. Median overall survival of 14.8 months (4.1− 22.2+). Treatment related adverse events included: reversible grade 1/2 non-hematologic toxicity consisting of: nausea, diarrhea, constipation, myalgia and fatigue. 19 pts with grade 3/4 neutropenia and 9 pts with grade 3/4 thrombocytopenia. Median duration of therapy is 6 months (2 - 22). Conclusion: Lenalidomide was well tolerated. Anti-tumor activity has been demonstrated by the following: tumor regression and delayed TTP. The tumor effect was also demonstrated as a second line therapy following cytokine failure. [Table: see text]
Collapse
Affiliation(s)
- L. Marsh
- Methodist Hospital Research Institute, Houston, TX; Celgene Corporation, Summit, NJ
| | - M. Khan
- Methodist Hospital Research Institute, Houston, TX; Celgene Corporation, Summit, NJ
| | - M. Needle
- Methodist Hospital Research Institute, Houston, TX; Celgene Corporation, Summit, NJ
| | - R. Amato
- Methodist Hospital Research Institute, Houston, TX; Celgene Corporation, Summit, NJ
| |
Collapse
|
46
|
Teh BT, Yang XJ, Tan M, Kim HL, Stadler W, Vogelzang NG, Amato R, Figlin R, Belldegrun A, Rogers CG. Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. T. Teh
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - X. J. Yang
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - M. Tan
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - H. L. Kim
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - W. Stadler
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - N. G. Vogelzang
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - R. Amato
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - R. Figlin
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - A. Belldegrun
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - C. G. Rogers
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
47
|
Doh LS, Amato R, Paulino AC, Teh BS. Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology (Williston Park) 2006; 20:603-13; discussion 613, 616, 619-20 passsim. [PMID: 16773845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality. More effective treatment approaches are needed. Traditionally, whole-brain radiotherapy has been used for palliation. With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes. This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes. Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed.
Collapse
|
48
|
Amato R, Ciaramella A, Deniskina N, Del Mondo C, di Bernardo D, Donalek C, Longo G, Mangano G, Miele G, Raiconi G, Staiano A, Tagliaferri R. A multi-step approach to time series analysis and gene expression clustering. Bioinformatics 2006; 22:589-96. [PMID: 16397005 DOI: 10.1093/bioinformatics/btk026] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
MOTIVATION The huge growth in gene expression data calls for the implementation of automatic tools for data processing and interpretation. RESULTS We present a new and comprehensive machine learning data mining framework consisting in a non-linear PCA neural network for feature extraction, and probabilistic principal surfaces combined with an agglomerative approach based on Negentropy aimed at clustering gene microarray data. The method, which provides a user-friendly visualization interface, can work on noisy data with missing points and represents an automatic procedure to get, with no a priori assumptions, the number of clusters present in the data. Cell-cycle dataset and a detailed analysis confirm the biological nature of the most significant clusters. AVAILABILITY The software described here is a subpackage part of the ASTRONEURAL package and is available upon request from the corresponding author. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- R Amato
- Dipartimento di Scienze Fisiche, University of Naples Federico II, Naples, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Doh L, Paulino A, Gonzalez M, Amato R, Butler B, Teh B. Palliative Brachytherapy and External Beam Radiotherapy for Patients with Endobronchial Obstruction from Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys 2005. [DOI: 10.1016/j.ijrobp.2005.07.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A Molecular Classification of Papillary Renal Cell Carcinoma. Cancer Res 2005; 65:5628-37. [PMID: 15994935 DOI: 10.1158/0008-5472.can-05-0533] [Citation(s) in RCA: 165] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphologic classification of PRCC into type 1 and 2 tumors has been recently proposed, but its biological relevance remains uncertain. We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analyses. Comparative genomic microarray analysis was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples with 15 independent tumors. We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histologic subtypes: type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumors. The second class, with poor survival, corresponded to high-grade type 2 tumors (n = 11). Dysregulation of G1-S and G2-M checkpoint genes were found in class 1 and 2 tumors, respectively, alongside characteristic chromosomal aberrations. We identified a seven-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in class 1 tumors and of topoisomerase IIalpha in class 2 tumors. We report two molecular subclasses of PRCC, which are biologically and clinically distinct and may be readily distinguished in a clinical setting.
Collapse
Affiliation(s)
- Ximing J Yang
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Illinois, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|